The Top 5 Biosimilar Articles for the Week of July 18
Here are the top 5 biosimilar articles for the week of July 18, 2022.
Hi, I’m Hayden Klein for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of July 18, 2022.
Number 5: Abstracts from the European Hematology Association Congress 2022 confirmed comparable safety and effectiveness profiles between 2 rituximab biosimilars and the reference product (Rituxan) in patients with large B-cell lymphoma.
Number 4: Two experts in biosimilar intellectual property (IP) law broke down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.
Number 3: The 2022 “Trends in Biosimilars Report Preview” said health care savings from the use of biosimilars climbed to $3 billion in the second quarter of 2022, for a total of $18 billion over the past 6 years.
Number 2: A real-world study on Pfizer and Celltrion Healthcare’s infliximab biosimilar (infliximab-dyyb, Inflectra; CT-P13) demonstrated positive clinical and patient-reported outcomes in patients with inflammatory bowel disease in the United States and Canada.
Number 1: Posters from the American Society of Clinical Oncology’s annual meeting showed the safety and efficacy of a trastuzumab biosimilar and a denosumab biosimilar in different types of cancer.
To read all of these articles and more, visit centerforbiosimilars.com.
